Original title:&nbsp;Balloon aortic valvuloplasty in the era of transcatheter aortic valve replacement: Acute and long-term outcomes.&nbsp;Reference:&nbsp;H&eacute;l&egrave;ne Eltchaninoff et al. Am Heart J 2014;167:235-40. Late 80s &nbsp;initial enthusiasm in aortic valvuloplasty was quickly tempered with the publication of several studies showing a high rate of complications, poor durability and little or no impact on survival. Since<a href="https://solaci.org/en/2014/02/05/results-of-aortic-valvuloplasty-in-the-era-of-tavi/" title="Read more" >...</a>

Original title:&nbsp;Automated 3-Dimensional Aortic Annular Assessment by Multidetector Computed&nbsp;Tomography in Transcatheter Aortic Valve Implantation.&nbsp;Reference:&nbsp;Yusuke Watanabe et al.&nbsp;J Am Coll Cardiol Intv 2013;6:955&ndash;64. Percutaneous aortic valve implantation ( TAVI ) has emerged as an alternative for patients with severe aortic stenosis and high surgical risk. While this technique was improved over the time, residual paravalvular regurgitation<a href="https://solaci.org/en/2013/09/26/automatic-measurement-of-the-aortic-annulus-by-tac-more-precisely-to-choose-the-correct-valve-size/" title="Read more" >...</a>

Original title:&nbsp;Transcatheter Aortic Valve Implantation for Pure Severe Native Aortic Valve Regurgitation.&nbsp;Reference:&nbsp;David A. Roy et al. J Am Coll Cardiol 2013. Article in press. Percutaneous aortic valve replacement (TAVI) has become a standard treatment for patients with severe aortic stenosis and a high surgical risk. However for those patients who have pure aortic insufficiency, (failure<a href="https://solaci.org/en/2013/02/21/tavi-also-for-pure-aortic-insufficiency/" title="Read more" >...</a>

Original title:&nbsp;Trends in outcome after transfemoral transcatheter aortic valve implantation. Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATICPlus) initiative.&nbsp;Reference:&nbsp;Nicolas M. Van Mieghem et al. Am Heart J 2012;0:1-10. Article in press. Since its introduction in 2002, Transfemoral Transcatheter Aortic Valve Implantation (TAVI) has turned into a viable and safe strategy to treat patients with severe acute stenosis and<a href="https://solaci.org/en/2013/01/15/transfemoral-transcatheter-aortic-valve-implantation-more-experience-and-better-results/" title="Read more" >...</a>

Original title:&nbsp;Impact of Post-Procedural Aortic Regurgitation on Mortality Alter Trancatheter Aortic Valve Implantation&nbsp;Reference:&nbsp;Kentaro Hayashida, et al. J Am Coll Interv 2012;5:1247-56 Transcatheter aortic valve implantation (TAVI) sprung up as a valid strategy to treat patients with severe high risk AS (aortic stenosis). However, residual aortic regurgitation (post AR) and post-dilation remain unsolved.&nbsp; Between October 2006<a href="https://solaci.org/en/2013/01/15/aortic-insufficiency-has-a-poor-prognosis-in-tavi/" title="Read more" >...</a>

Reference:&nbsp;Buellesfeld y colaboradores (JACC in press). Percutaneous aortic valve replacement (AVR) is an innovative technique for the treatment of severe aortic stenosis (SAS); this technique has been incorporated with great enthusiasm in clinical practice, particularly for patients with excessive surgical risks. Due to the proximity of the aortic valve, AV node and His bundle, there<a href="https://solaci.org/en/2012/10/01/the-impact-of-permanent-pacemaker-implantation-in-patients-undergoing-percutaneous-aortic-valve-replacement/" title="Read more" >...</a>

Reference: Durand E. et al (JACC CV interventions 2012 in press)1 When percutaneous aortic valve replacement (AVR) first began the procedure required a large-bore sheath (22-24 F), being the most frequent surgical strategy when using general anesthesia. Continuous technological advances achieved the miniaturization of devices which allow the procedure to be performed with a much<a href="https://solaci.org/en/2012/10/01/aortic-transfemoral-valve-replacement-using-edwards-sapien-and-edwards-sapien-xt-prosthesis-local-anesthesia/" title="Read more" >...</a>